Hormonal
High responders to 12 weeks of resistance training exhibit differential regulation of specific microRNAs (miR-378, miR-29a, miR-26a, and miR-451) compared to low responders, with miR-378 levels strongly correlating with lean body mass gains.
Resistance training results vary significantly between individuals. This study suggests that 'high responders' maintain stable levels of certain microRNAs (like miR-378) during training, which correlates with greater muscle gain. Low responders show different molecular adaptations (downregulation of miR-378, upregulation of miR-451). If you are not seeing expected muscle gains, it may be due to these underlying molecular differences rather than just effort. Consistency is key, as your body may be using different molecular pathways to adapt.
miR-378, miR-29a, and miR-26a were downregulated in low responders and unchanged in high responders, while miR-451 was upregulated only in low responders... the training-induced change in miR-378 abundance was positively correlated with muscle mass gains in vivo.
Why this rating
Controlled clinical trial with blinded analysis and a relatively large sample size (n=56) stratified by response, though the mechanistic link to protein synthesis is inferred from target prediction.
Source
High responders to resistance exercise training demonstrate differential regulation of skeletal muscle microRNA expression
Peter K. Davidsen et al. · Journal of Applied Physiology · 2010
DOI 10.1152/japplphysiol.00901.2010
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →